glp-1 medication competitors pharmaceutical companies The Next Big Weight Loss Drug Stocks 3 Companies at the Forefront

18 They found that patients taking semaglutide were more likely to develop NAION at two, three and four years after initiation of treatment, with a cumulative HR of 2.22 after four years compared to control (n=45 vs 29)

Article 8

PubMed, Sheikh, Haroon I., et al

[24] [25] These laboratory findings suggest potential protective mechanisms, though their clinical relevance in humans remains uncertain

They are not suitable for individuals who are pregnant, breastfeeding, or have a personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2)

Compounded versions may have slightly different viscosity than the brand-name product, which can affect how the injection feels at different sites